Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Stada Arzneimittel AG (OTC: STDAF).

Full DD Report for STDAF

You must become a subscriber to view this report.


Recent News from (OTC: STDAF)

Stada Arzneimittel AG 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Stada Arzneimittel AG in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 09 2018 15:11
Stada Arzneimittel's (STDAF) CEO Claudio Albrecht on Q1 2018 Results - Earnings Call Transcript
Stada Arzneimittel AG (STDAF) Q1 2018 Earnings Conference Call May 03, 2018, 04:00 AM ET Executives Leslie Iltgen - Head-IR Mark Keatley - CFO Claudio Albrecht - CEO Analysts Naveed Mukhtar - PGIM Ulrich Huwald - Warburg Research Philippe Lanone - Natixis Presentatio...
Source: SeekingAlpha
Date: May, 05 2018 00:08
Stada Arzneimittel AG 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Stada Arzneimittel AG in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 03 2018 23:23
Stada Arzneimittel AG reports Q1 results
Stada Arzneimittel AG ( OTCPK:STDAF ): Q1 EPS of  € 0.98 More news on: Stada Arzneimittel AG, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 03 2018 08:00
Stada Arzneimittel's (STDAF) CEO Claudio Albrecht on Q4 2017 Results - Earnings Call Transcript
Stada Arzneimittel AG (STDAF) Q4 2017 Earnings Conference Call March 8, 2018 6:00 AM ET Executives Leslie Iltgen – Head-Investor Relations Mark Keatley – Chief Financial Officer Claudio Albrecht – Chief Executive Officer Analysts Naveed Mukhtar –...
Source: SeekingAlpha
Date: March, 09 2018 05:07
Stada Arzneimittel AG 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Stada Arzneimittel AG in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: March, 08 2018 14:30
Stada Arzneimittel AG reports Q4 results
Stada Arzneimittel AG ( OTCPK:STDAF ): Q4 EPS of €0.81 More news on: Stada Arzneimittel AG, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: March, 08 2018 06:52
STADA Arzneimittel's (STDAF) CEO Claudio Albrecht on Q3 2016 Results - Earnings Call Transcript
STADA Arzneimittel AG (STDAF) Q3 2017 Earnings Conference Call November 9, 2017 07:00 am ET Executives Leslie Iltgen - Head, IR Claudio Albrecht - Chairman, CEO Mark Keatley - CFO Analysts Thomas Maul - DZ Bank Ulrich Huwald - Warburg Research GmbH Ronald Chong - Deutsc...
Source: SeekingAlpha
Date: November, 09 2017 11:11
Stada Arzneimittel AG 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Stada Arzneimittel AG in conjunction with their 2017 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 09 2017 06:43

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1887.8087.8087.8087.80300
2018-12-17N/A90.35N/AN/A0
2018-12-14N/A90.35N/AN/A0
2018-12-13N/A90.35N/AN/A0
2018-12-12N/A90.35N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-15100100100.0000Short
2018-09-181010100.0000Short
2018-07-25100100100.0000Short
2018-03-08140140100.0000Short
2018-02-02100100100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on STDAF.


About Stada Arzneimittel AG (OTC: STDAF)

Logo for Stada Arzneimittel AG (OTC: STDAF)

STADA Arzneimittel AG is an international publicly listed company. At the center of the business activities are the pharmaceutical and, in particular, the generics market with sustainable growth potential.

 

Contact Information

 

 

Current Management

  • Hartmut Retzlaff / CEO
  • Helmut Kraft / CFO

Current Share Structure

  • Market Cap: $6,273,489,258 - 03/16/2018
  • Issue and Outstanding: 58,878,360 - 03/31/2011

 



Daily Technical Chart for (OTC: STDAF)

Daily Technical Chart for (OTC: STDAF)


Stay tuned for daily updates and more on (OTC: STDAF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: STDAF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in STDAF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of STDAF and does not buy, sell, or trade any shares of STDAF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/